Market Cap 2.85B
Revenue (ttm) 63.52M
Net Income (ttm) -376.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.10%
Debt to Equity Ratio 0.00
Volume 1,549,700
Avg Vol 2,688,892
Day's Range N/A - N/A
Shares Out 101.16M
Stochastic %K 55%
Beta 2.25
Analysts Strong Sell
Price Target $46.14

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8775
Website: beamtx.com
Address:
238 Main Street, Cambridge, United States
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:45 PM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 2:36 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $28.35 Contracts: $BEAM January 15, 2027 $30 Calls Scale in: $8.21- $10.04 Scale out: $12.77-$16.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Almondbutter
Almondbutter Oct. 23 at 4:58 PM
$BEAM October 31 is coming
0 · Reply
bolochlainn2
bolochlainn2 Oct. 23 at 3:41 AM
$BEAM Beam Therapeutics’ acquisition? Beam Therapeutics sickle cell program (BEAM-101.) was designed to compete in an area that’s now functionally saturated — CRISPR Therapeutics and Vertex already got Casgevy approved, and Bluebird Bio’s Lyfgenia is also on the market. With those therapies available, Beam’s clinical programs in that indication are more of a validation exercise for their base editing platform than a major commercial opportunity. So the acquisition logic would be: • Beam’s market cap is now relatively modest (~$3B), • They have clinical validation coming in • They own deep IP in base editing. • Big pharma companies could see this as a long-term bet on next-gen gene editing tech. In other words, Beam’s pipeline may not justify independence, but the platform absolutely could justify acquisition— particularly by a company that missed the CRISPR wave and wants to leapfrog to the next generation. With Biotech M&A heating up - this maybe one to watch .
0 · Reply
Digger75
Digger75 Oct. 22 at 7:03 PM
$BEAM this is the one !!
0 · Reply
Trendrebel
Trendrebel Oct. 22 at 3:19 PM
$BEAM Must fill the gap ( 26.50 ) before any kind of rebound
0 · Reply
Capitulation_0
Capitulation_0 Oct. 22 at 2:48 PM
$BEAM adding. pretty dumb action
0 · Reply
Trendrebel
Trendrebel Oct. 22 at 9:51 AM
$BEAM Something odd here ! Stockprice skyrocket, but est. revenue keeps dropping. PEG & P/B are extreme high. I probably miss something hidden behind the curtain
1 · Reply
Digger75
Digger75 Oct. 22 at 12:07 AM
0 · Reply
victorgn
victorgn Oct. 21 at 5:18 PM
$BEAM Rising back to $35
0 · Reply
Latest News on BEAM
Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Oct 22, 2025, 10:19 AM EDT - 2 days ago

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential


Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:01 AM EDT - 8 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering


BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:45 PM
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 2:36 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $28.35 Contracts: $BEAM January 15, 2027 $30 Calls Scale in: $8.21- $10.04 Scale out: $12.77-$16.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Almondbutter
Almondbutter Oct. 23 at 4:58 PM
$BEAM October 31 is coming
0 · Reply
bolochlainn2
bolochlainn2 Oct. 23 at 3:41 AM
$BEAM Beam Therapeutics’ acquisition? Beam Therapeutics sickle cell program (BEAM-101.) was designed to compete in an area that’s now functionally saturated — CRISPR Therapeutics and Vertex already got Casgevy approved, and Bluebird Bio’s Lyfgenia is also on the market. With those therapies available, Beam’s clinical programs in that indication are more of a validation exercise for their base editing platform than a major commercial opportunity. So the acquisition logic would be: • Beam’s market cap is now relatively modest (~$3B), • They have clinical validation coming in • They own deep IP in base editing. • Big pharma companies could see this as a long-term bet on next-gen gene editing tech. In other words, Beam’s pipeline may not justify independence, but the platform absolutely could justify acquisition— particularly by a company that missed the CRISPR wave and wants to leapfrog to the next generation. With Biotech M&A heating up - this maybe one to watch .
0 · Reply
Digger75
Digger75 Oct. 22 at 7:03 PM
$BEAM this is the one !!
0 · Reply
Trendrebel
Trendrebel Oct. 22 at 3:19 PM
$BEAM Must fill the gap ( 26.50 ) before any kind of rebound
0 · Reply
Capitulation_0
Capitulation_0 Oct. 22 at 2:48 PM
$BEAM adding. pretty dumb action
0 · Reply
Trendrebel
Trendrebel Oct. 22 at 9:51 AM
$BEAM Something odd here ! Stockprice skyrocket, but est. revenue keeps dropping. PEG & P/B are extreme high. I probably miss something hidden behind the curtain
1 · Reply
Digger75
Digger75 Oct. 22 at 12:07 AM
0 · Reply
victorgn
victorgn Oct. 21 at 5:18 PM
$BEAM Rising back to $35
0 · Reply
Dg949494
Dg949494 Oct. 21 at 3:25 PM
$BEAM me up scotty
0 · Reply
Publicola29
Publicola29 Oct. 21 at 12:37 PM
$BEAM love to see beam pumping because I own $PRME I know prime can do everything that Beam can do and so much more so would love to see Beam get to a $5 billion market cap because that mean prime is going to at least 10 billion. Both will be much much higher from here
0 · Reply
darioras
darioras Oct. 21 at 12:36 PM
$BEAM I can see a gold crossing yesterday, more upward trend has to be expected?
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 21 at 11:54 AM
$KRYS another one in the same sector, with much more promising-looking chart. $BEAM had a monster 17.86% day.
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 21 at 11:54 AM
Anyone been following $BEAM ? Beyond pissed at myself for now buying commons around $16. Been wanting equity for ages but never pulled trigger. Gene editing company - huge in the future.
0 · Reply
Dg949494
Dg949494 Oct. 21 at 5:54 AM
$BEAM just bought 400 shares. This might double right quick.
1 · Reply
RunnerSignals
RunnerSignals Oct. 21 at 3:40 AM
$BEAM flashing golden cross! ✨
0 · Reply
LastResort
LastResort Oct. 21 at 12:36 AM
$BEAM $VKTX yall over at BEAM blocked this 🤡 yet?
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Oct. 20 at 5:21 PM
$BEAM almost 50% in 5 weeks. More to go. Long
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 12:52 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $25.98 Contracts: $BEAM January 15, 2027 $27 Calls Scale in: $8.50- $10.39 Scale out: $13.23-$17.01 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 3:49 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $25.79 Contracts: $BEAM January 15, 2027 $27 Calls Scale in: $8.87- $10.84 Scale out: $13.79-$17.73 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 16 at 9:25 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BEAM Current Share Price: $27.19 Contracts: $BEAM January 15, 2027 $30 Calls Scale in: $8.32- $10.16 Scale out: $12.94-$16.63 Can Easily Capture: 60% ROI Blended DTE: 456 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply